TOXICITY AND IMMUNOGENICITY OF MONOCLONAL ANTIMELANOMA ANTIBODY-RICIN A-CHAIN IMMUNOTOXIN IN RATS
- 1 March 1987
- journal article
- research article
- Vol. 47 (5) , 1377-1382
Abstract
This study was performed to assess the subacute toxicity and immunogenicity in rats of XOMAZYME-MEL, an antimelanoma monoclonal antibody-ricin A chain immunotoxin. Female Sprague-Dawley rats received 14 consecutive daily i.v. injections of XOMAZYME-MEL at doses of 5 mg/kg/day, 1 mg/kg/day, or normal saline. Animals from each dose group were sacrificed on days 8, 15, and 22. The low dose of immuotoxin was well tolerated and produced only minimal signs of toxicity. Side effects in animals receiving the high dose of immunotoxin consisted of transient weight loss, peripheral edema, leukocytosis, hypoalbuminemia, and mildly elevated liver function tests. Histological findings in these animals included cytoplasmic vacuolization of hepatocytes, focal myocardial and skeletal muscle degeneration, and renal deposits of proteinaceous casts. The administration of immunotoxin resulted in the appearance of anti-mouse and antiricin A chain immunoglobulin binding activity in the sera of treated animals. This study documents the systemic effect of the multiple-dose administration of a ricin A chain immunotoxin in rats.This publication has 9 references indexed in Scilit:
- EFFECTS OF MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA1984
- Antibody formation against the cytotoxic proteins abrin and ricin in humans and miceInternational Journal of Cancer, 1983
- PHASE-I CLINICAL TRIAL OF MONOCLONAL ANTIBODY IN TREATMENT OF GASTROINTESTINAL TUMOURSThe Lancet, 1982
- INVIVO EFFECTS OF MURINE HYBRIDOMA MONOCLONAL-ANTIBODY IN A PATIENT WITH T-CELL LEUKEMIA1981
- Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.The Journal of Immunology, 1980
- Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin.Proceedings of the National Academy of Sciences, 1980
- Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin.Proceedings of the National Academy of Sciences, 1980
- Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.Proceedings of the National Academy of Sciences, 1980
- Antibody-Linked Cytotoxic Agents in the Treatment of Cancer: Current Status and Future Prospects2JNCI Journal of the National Cancer Institute, 1978